Transgrediens et progrediens palmoplantar keratoderma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:495OMIM:133200Q82.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Transgrediens et progrediens palmoplantar keratoderma (PPK) is a rare inherited skin disorder characterized by marked thickening of the skin on the palms of the hands and soles of the feet (palmoplantar keratoderma) that extends beyond the palmoplantar margins onto the dorsal surfaces of the hands and feet (transgrediens) and progressively spreads to adjacent areas over time (progrediens). This condition is also known as Greither disease or Greither syndrome, named after the physician who first described it. The keratoderma typically presents in early childhood and tends to worsen with age, sometimes extending onto the wrists, Achilles tendon area, and knees. The disease primarily affects the integumentary system (skin). Key clinical features include diffuse, symmetric thickening of the palms and soles with a characteristic spreading pattern beyond the normal palmoplantar boundaries. Patients may also develop hyperhidrosis (excessive sweating) of the affected areas, which can lead to secondary fungal infections and malodor. The thickened skin can cause significant discomfort, reduced hand dexterity, and difficulty walking. Some patients may also exhibit mild involvement of other keratinized surfaces. Greither disease has been associated with mutations in the keratin gene KRT1 and in some cases other genes involved in epidermal differentiation. Treatment is primarily symptomatic and supportive. Topical keratolytic agents such as salicylic acid, urea-based creams, and topical retinoids are commonly used to reduce skin thickness. Oral retinoids (such as acitretin) may be prescribed in more severe cases. Regular mechanical debridement by a dermatologist or podiatrist can help manage the thickened skin. There is currently no curative treatment, and management focuses on improving quality of life and maintaining functional use of the hands and feet.

Also known as:

Clinical phenotype terms— hover any for plain English:

Diffuse palmoplantar hyperkeratosisHP:0007447Facial erythemaHP:0001041Hyperconvex nailHP:0001795Dystrophic toenailHP:0001810Recurrent bacterial skin infectionsHP:0005406Nonepidermolytic palmoplantar hyperkeratosisHP:0007404Plantar hyperkeratosisHP:0007556Dystrophic fingernailsHP:0008391Palmar hyperkeratosisHP:0010765Recurrent cutaneous fungal infectionsHP:0011370Flexion contracture of fingerHP:0012785Angular cheilitisHP:0030318OnychogryphosisHP:0001805Amniotic constriction ringHP:0009775Lichenoid skin lesionHP:0031452
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Transgrediens et progrediens palmoplantar keratoderma.

View clinical trials →

No actively recruiting trials found for Transgrediens et progrediens palmoplantar keratoderma at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Transgrediens et progrediens palmoplantar keratoderma community →

No specialists are currently listed for Transgrediens et progrediens palmoplantar keratoderma.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Transgrediens et progrediens palmoplantar keratoderma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Transgrediens et progrediens palmoplantar keratodermaForum →

No community posts yet. Be the first to share your experience with Transgrediens et progrediens palmoplantar keratoderma.

Start the conversation →

Latest news about Transgrediens et progrediens palmoplantar keratoderma

No recent news articles for Transgrediens et progrediens palmoplantar keratoderma.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Transgrediens et progrediens palmoplantar keratoderma

What is Transgrediens et progrediens palmoplantar keratoderma?

Transgrediens et progrediens palmoplantar keratoderma (PPK) is a rare inherited skin disorder characterized by marked thickening of the skin on the palms of the hands and soles of the feet (palmoplantar keratoderma) that extends beyond the palmoplantar margins onto the dorsal surfaces of the hands and feet (transgrediens) and progressively spreads to adjacent areas over time (progrediens). This condition is also known as Greither disease or Greither syndrome, named after the physician who first described it. The keratoderma typically presents in early childhood and tends to worsen with age, so

How is Transgrediens et progrediens palmoplantar keratoderma inherited?

Transgrediens et progrediens palmoplantar keratoderma follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Transgrediens et progrediens palmoplantar keratoderma typically begin?

Typical onset of Transgrediens et progrediens palmoplantar keratoderma is childhood. Age of onset can vary across affected individuals.